Sign in
Active, not recruitingNo phase

MitraClip REPAIR MR Study

Key facts

Who runs it
Abbott Medical Devices
Where
Albany, Ann Arbor, Asheville, Atlanta, Austin, Bay Shore, Birmingham, Boston, Camden, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Columbus, Denver, Detroit, Durham, Harrisburg, Houston, Indianapolis, Jacksonville, Kansas City, La Jolla, Minneapolis, Mobile, Morgantown, Morristown, Murray, Naples, Nashville, Neptune City, New Haven, New York, Norfolk, Oklahoma City, Phoenix, Pittsburgh, Rochester, Roslyn, Royal Oak, Sacramento, San Francisco, Seattle, Springfield, Stanford, Thousand Oaks, Tucson, Wichita, and Wynnewood, United StatesSee the 63 sitesAlso in 3 other countries, 11 sites
Trial code
Status
Active, not recruiting
People taking part
500 people, planned
Started
21 Jul 2020
Expected to end
Dec 2035
Type of study
Interventional, 2 groups
Treatments tested
  • MitraClip™ device implantation
  • Mitral Valve Repair Surgery
Record updated
15 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Subject has severe (Grade III or greater per the ASE criteria, which includes severity grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal mechanism of action is a degenerative mitral valve) as assessed by the ECL
  • The cardiac surgeon of the Site Heart Team (consisting of at least one interventionalist, and one cardiac surgeon) has confirmed that the subject is a candidate for mitral valve surgery and the EC have confirmed that the subject's mitral valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high certainty of achieving MR ≤ mild
  • Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%, pulmonary artery systolic pressure > 50 mmHg, or LVESD > 40 mm
  • Subject is at moderate surgical risk defined as being at least 75 years of age at the time of EC review. If younger than 75 years, then the subject should have:; Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) Repair Score ≥ 2%, OR; Presence of other comorbidities which may introduce a potential surgery-specific impediment
  • Subject provides written informed consent
  • Subject is ≥ 18 years of age

Who cannot take part

  • Concomitant severe tricuspid valve regurgitation
  • Subjects who have concurrent coronary artery disease that needs to be treated may be included provided the subjects are eligible for both percutaneous coronary intervention (PCI) and coronary artery bypass surgery. Subjects randomized to the device group, must undergo PCI before the MitraClip™ device procedure. Subjects randomized to the surgical (control) arm may undergo coronary artery revascularization during mitral valve repair surgery
  • Surgical procedure performed in the past 30 days
  • Need for emergency surgery for any reason
  • Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  • Acute myocardial infarction in the past 12 weeks
  • Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or tricuspid valve disease
  • Renal insufficiency requiring dialysis
  • Active infections requiring current antibiotic therapy
  • Ejection fraction <30%
  • Subject is currently participating in another clinical investigation
  • Subject has ischemic or non-ischemic secondary MR
  • Severe mitral annular calcification
  • Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would interfere with the catheter or ipsilateral DVT
  • Transesophageal echocardiography (TEE) is contraindicated
  • Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction, cardiogenic shock, or the need for inotropic support or IABP
  • Systolic anterior motion of the mitral valve
  • Hypertrophic cardiomyopathy

Where in United States

Also in 3 other countries, 11 sites

  • Albany Medical CenterAlbany, United States
  • University of Michigan Medical CenterAnn Arbor, United States
  • Mission Health & HospitalsAsheville, United States
  • Piedmont Heart InstituteAtlanta, United States
  • Ascension Texas Cardiovascular ResearchAustin, United States
  • South Shore University HospitalBay Shore, United States
  • University Hospital - Univ. of Alabama at Birmingham (UAB)Birmingham, United States
  • Brigham and Women's HospitalBoston, United States
  • Massachusetts General HospitalBoston, United States
  • Cooper University HospitalCamden, United States
  • Carolinas Medical CenterCharlotte, United States
  • University of Virginia Medical CenterCharlottesville, United States
  • Northwestern Memorial HospitalChicago, United States
  • Christ HospitalCincinnati, United States
  • University Hospitals Cleveland Medical Center*Cleveland, United States
  • Mt Carmel EastColumbus, United States
  • Saint Joseph HospitalDenver, United States
  • Henry Ford HealthDetroit, United States
  • Duke University Medical CenterDurham, United States
  • Pinnacle Health Cardiovascular Institute, Inc.Harrisburg, United States
  • HCA Houston Healthcare Medical CenterHouston, United States
  • Houston MethodistHouston, United States
  • UTHealth Memorial HermannHouston, United States
  • Ascension St. VincentIndianapolis, United States
  • Baptist Medical CenterJacksonville, United States
  • Kansas University Medical CenterKansas City, United States
  • Scripps HealthLa Jolla, United States
  • Abbott-Northwestern HospitalMinneapolis, United States
  • Cardiology Associates of Mobile, Inc.Mobile, United States
  • West Virginia University HospitalMorgantown, United States
  • Morristown Medical CenterMorristown, United States
  • Intermountain Medical CenterMurray, United States
  • NCH Healthcare SystemNaples, United States
  • Ascension Saint ThomasNashville, United States
  • TriStar Centennial Medical centerNashville, United States
  • Vanderbilt Heart & Vascular InstituteNashville, United States
  • Jersey Shore University Medical CenterNeptune City, United States
  • Yale New Haven HospitalNew Haven, United States
  • New York Presbyterian/Columbia University Medical CenterNew York, United States
  • NYU Langone HealthNew York, United States
  • Sentara Norfolk General HospitalNorfolk, United States
  • Integris Baptist Medical CenterOklahoma City, United States
  • Arizona Cardiovascular Research CenterPhoenix, United States
  • Banner-University Medical Center PhoenixPhoenix, United States
  • St. Josephs Hospital and Medical CenterPhoenix, United States
  • Allegheny General Hospital - ASRIPittsburgh, United States
  • UPMCPittsburgh, United States
  • Rochester Regional HealthRochester, United States
  • St. Francis HospitalRoslyn, United States
  • Beaumont Hospital, Royal OakRoyal Oak, United States
  • Mercy General HospitalSacramento, United States
  • Sutter Medical Center SacramentoSacramento, United States
  • University of California, Davis Medical CenterSacramento, United States
  • University of California at San FranciscoSan Francisco, United States
  • Swedish Medical CenterSeattle, United States
  • The Heart Institute at Virginia MasonSeattle, United States
  • Prairie Education & Research CooperativeSpringfield, United States
  • Stanford University Medical CenterStanford, United States
  • Los Robles Regional Medical CenterThousand Oaks, United States
  • Tucson Medical CenterTucson, United States
  • Cardiovascular Research Institute of KansasWichita, United States
  • Via Christi Regional Medical Center - St. Francis CampusWichita, United States
  • Lankenau Institute for Medical ResearchWynnewood, United States

About the trial

What the trial wants to find out

The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.

The 2 groups in the trial

  • Control ArmOther group

    Mitral Valve Repair Surgery

    Treatment: Mitral Valve Repair Surgery

  • Device ArmTreatment being tested

    MitraClip™ device implantation

    Treatment: MitraClip™ device implantation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Percutaneous MitraClip Device or Surgical Mitral Valve REpair in PAtients With PrImaRy MItral Regurgitation Who Are Candidates for Surgery (REPAIR MR)
Publications
Record updated
15 May 2026